Therapeutic Areas / All therapeutic areas

Your needs,
our answers

Alfasigma is a key player in the Italian pharmaceutical industry, boasting a portfolio ranging from prescription specialties and over-the-counter products all the way to nutraceuticals.

In Italy, it is a market leader for prescription drugs, boasting a presence in many primary care therapeutic areas, as well as for well-known over-the-counter products such as Biochetase, Neo-Borocillin, Dicloreum and Yovis.

Worldwide, Alfasigma has products in the following therapeutic areas


Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)


Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions


We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis


In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles

Nutraceuticals & Medical foods

With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue

Read More

Our Research & Development Department is focused on three main therapeutic areas: gastroenterology, vascular disease & neuroscience disorders.
We are an international pharmaceutical company. Our headquarters are based in Italy, where we are deeply rooted as one of the leading companies in primary care.
Alfasigma is a leading company in Contract Manufacturing, a unique partner in outsourcing activities for the manufacturing of nearly all pharmaceutical forms.

You’re entering Alfasigma global website

I agree